Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2) Conference Proceedings uri icon

Overview

Authors

  • Authorship

    • GANE EJ
    • LAURSEN AL
    • GERSTOFT J
    • GAO W
    • HUANG H-C
    • FITZGERALD B
    • LI JJ
    • WAN S
    • DUTKO F
    • NGUYEN B-YT
    • WAHL J
    • PIANKO S
    • BARR E
    • BUTTERTON JR
    • ESTEBAN R
    • ROBERTS SK
    • DR Alex Thompson
    • ZEUZEM S
    • ZUCKERMAN E
    • BEN ARI Z
    • FOSTER GR
    • AGARWAL K

Published in

  • Hepatology

Time

Date/time value

  • 2015

Additional Document Info

Parent Title

  • HEPATOLOGY

Volume

  • 62

Issue

  • 6

Publisher

  • WB Saunders Co